FGFR3 Antibodies in Neuropathy: What to Do With Them?
ABSTRACT
OBJECTIVES
To describe the variability of fibroblast growth factor receptor 3 (FGFR3) antibody titers in a small series of patients.
METHODS
We performed a retrospective review of patients with neuropathy and positive FGFR3 antibodies.
RESULTS
We report 7 patients (3 women) with an age range 44-81 years. Symptoms were acute onset in 3 and subacute onset in 4 patients. Five had neuropathic pain. Examination revealed normal large fiber function to mild/moderate predominantly sensory neuropathy and ataxia in one patient. Electrodiagnostic studies revealed normal large fiber function (3), demyelinating neuropathy (1), and mild/moderate axonal neuropathy (3). Four patients had high and 3 patients had low FGFR3 titers. Repeat testing revealed absence of antibodies in 2 patients and a significant reduction in one patient without any intervening immunotherapy.
CONCLUSIONS
Our case series highlights the variability and inconsistency in FGFR3 antibody titers through enzyme-linked immunosorbent assay testing. These antibody titers should always be interpreted with caution in clinical context.
New answer by at University of Minnesota (October 29, 2022)
Assuming no other cause of neuropathy has been found, the short answer is symptomatic treatment with meds for neuropathic pain like gabapentin, pregabalin, tricyclics, other a...